All Repatha Devices Launched at Reduced List Price

The Company report that 80% of current Repatha Medicare patients have access at the new reduced price.

Amgen announced that all Repatha (evolocumab) devices are now available at a 60% reduced list price. This includes the pre-filled syringe, the SureClick autoinjector, and the Pushtronex device, an on-body infusor with prefilled cartridge.

Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, is approved to reduce the risk of MI, stroke, and coronary revascularization in adults with established cardiovascular (CV) disease; as adjunct to diet, alone or in combination with other lipid-lowering therapies, in adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia [HeFH]) to reduce LDL-C; and as adjunct to diet and other LDL-lowering therapies, in patients with homozygous familial hypercholesterolemia (HoFH) requiring additional lowering of LDL-C.

The Company report that 80% of current Repatha Medicare patients have access at the new reduced price. More patients will be able to fill a Repatha prescription as large payers are reclassifying Repatha as a “non-specialty” therapy. The RepathaReady program is also available to help patients and providers better understand coverage support.

Murdo Gordon, EVP of Global Commercial Operations at Amgen added, “However, more must be done to help more patients get to a low fixed co-pay. We need continued engagement from all stakeholders – from healthcare professionals to payers to plans and to government agencies – to help ensure patients benefit from the lower list price to reduce their out-of-pocket costs.”

Repatha is available as a 140mg/mL single-use prefilled syringe, a 140mg/mL single-use prefilled SureClick autoinjector, and the 420mg/3.5mL single-use Pushtronex system.